Drug discovery of non-standard peptide with genetic code reprogramming

Abstract

This review discusses recent development of a new platform technology that enables us to discover "natural product-like" non-standard peptides against various therapeutic targets. This platform technology is referred to as RaPID system (Random non-standard Peptides Integrated Discovery) system, composed of FIT (Flexible In-vitro Translation) system coupled with an mRNA display. By means of this system, a library of macrocyclic peptides consisting of over trillion unique sequences could be constructed and rapidly screened for desired bioactive properties. We shall also discuss the importance of merging the non-standard peptide therapeutics with DDS as a perspective.